pbs_code,drug,brand,formulation,indication,treatment_phase,streamlined_code,online_application,authority_method,hospital_type,schedule_code,schedule_year,schedule_month
13308K,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Continuing treatment,14154,True,STREAMLINED,Public,4030,2024,AUGUST
13757C,tofacitinib,Xeljanz,Tablet 5 mg,juvenile idiopathic arthritis,Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9034L,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11516D,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,non-radiographic axial spondyloarthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11516D,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,non-radiographic axial spondyloarthritis,Continuing treatment,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10767Q,ustekinumab,Stelara,Injection 45 mg in 0.5 mL,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10767Q,ustekinumab,Stelara,Injection 45 mg in 0.5 mL,psoriatic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13720D,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
13065P,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled syringe,ankylosing spondylitis,Balance of supply (including switching formulation) where the full duration of treatment available under a particular treatment phase was not requested in the preceding prescription,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12217B,ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12217B,ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12217B,ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,ankylosing spondylitis,"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12217B,ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3428K,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3428K,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11375Q,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11375Q,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3449M,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Continuing Treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3449M,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13223Y,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,11604,True,STREAMLINED,Any,4030,2024,AUGUST
13223Y,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,11604,True,STREAMLINED,Any,4030,2024,AUGUST
11498E,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
11498E,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
11498E,infliximab,Remicade,Powder for I.V. infusion 100 mg,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
11197H,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
6448J,infliximab,Remicade,Powder for I.V. infusion 100 mg,ankylosing spondylitis,"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Remicade,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Remicade,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Remicade,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Remicade,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Remicade,Powder for I.V. infusion 100 mg,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6448J,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13228F,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
13228F,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
13228F,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
13315T,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Continuing treatment,14179,True,STREAMLINED,Private,4030,2024,AUGUST
13047Q,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled syringe,psoriatic arthritis,Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
6397Q,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6397Q,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
11675L,tofacitinib,Xeljanz,Tablet 5 mg,psoriatic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11675L,tofacitinib,Xeljanz,Tablet 5 mg,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12094M,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months) - in a patient of any weight being administered a subcutaneous form of this biological medicine,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12355G,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
12355G,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
12355G,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
12355G,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
12355G,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
13723G,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13723G,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13723G,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13723G,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13723G,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13723G,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13723G,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13723G,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13305G,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Continuing treatment,14164,True,STREAMLINED,Public,4030,2024,AUGUST
13735X,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
12775J,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13704G,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13704G,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13704G,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13704G,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13704G,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13704G,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10137M,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,ankylosing spondylitis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10137M,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5757B,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5757B,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9103D,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9103D,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3448L,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Continuing Treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3448L,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11690G,tofacitinib,Xeljanz,Tablet 5 mg,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11690G,tofacitinib,Xeljanz,Tablet 5 mg,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11690G,tofacitinib,Xeljanz,Tablet 5 mg,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11690G,tofacitinib,Xeljanz,Tablet 5 mg,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12329X,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
12329X,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
12329X,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
12329X,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
12329X,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
12763R,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
14285W,adalimumab,Abrilada,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
13686H,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,14567,True,STREAMLINED,Any,4030,2024,AUGUST
13686H,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,14567,True,STREAMLINED,Any,4030,2024,AUGUST
13686H,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,14567,True,STREAMLINED,Any,4030,2024,AUGUST
13686H,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,14567,True,STREAMLINED,Any,4030,2024,AUGUST
13686H,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,14567,True,STREAMLINED,Any,4030,2024,AUGUST
13299Y,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Continuing treatment,14093,True,STREAMLINED,Public,4030,2024,AUGUST
6367D,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6367D,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6367D,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6367D,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13687J,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13687J,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13687J,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13687J,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10058J,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10058J,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10058J,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10058J,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Continuing Treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10058J,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10058J,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12090H,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Continuing treatment in a patient weighing less than 30 kg,14084,True,STREAMLINED,Any,4030,2024,AUGUST
14235F,adalimumab,Abrilada,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
14235F,adalimumab,Abrilada,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
14235F,adalimumab,Abrilada,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
14235F,adalimumab,Abrilada,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10079L,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10079L,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10079L,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10079L,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
11202N,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Subsequent continuing treatment,9156,True,STREAMLINED,Any,4030,2024,AUGUST
12566J,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled pen,rheumatoid arthritis,"Balance of supply for Initial treatment, Continuing treatment - subcutaneous form",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3430M,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3430M,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3430M,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3430M,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8778B,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8778B,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8778B,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8778B,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12349Y,adalimumab,Amgevita,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
12792G,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12796L,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12796L,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13295R,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Continuing treatment,14155,True,STREAMLINED,Private,4030,2024,AUGUST
11489Q,infliximab,Remicade,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
11489Q,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
11489Q,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13339C,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Continuing treatment,14164,True,STREAMLINED,Public,4030,2024,AUGUST
13699B,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,rheumatoid arthritis,Subsequent continuing treatment,14604,True,STREAMLINED,Any,4030,2024,AUGUST
13722F,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13722F,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13722F,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13722F,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13722F,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13722F,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13722F,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13722F,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13722F,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13722F,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13722F,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13722F,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13722F,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13722F,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13722F,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10897M,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,ankylosing spondylitis,"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13214L,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,11523,True,STREAMLINED,Any,4030,2024,AUGUST
13214L,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,11523,True,STREAMLINED,Any,4030,2024,AUGUST
12444Y,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12444Y,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12444Y,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12444Y,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12444Y,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12444Y,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12444Y,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12444Y,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12444Y,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12444Y,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12444Y,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12444Y,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11560K,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,non-radiographic axial spondyloarthritis,Initial treatment - Initial 1 (New patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11560K,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,non-radiographic axial spondyloarthritis,"Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11560K,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,non-radiographic axial spondyloarthritis,Initial treatment - Initial 2 (Change or re-commencement of treatment after a break of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11560K,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,non-radiographic axial spondyloarthritis,Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12425Y,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12425Y,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12425Y,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12425Y,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12425Y,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12425Y,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12425Y,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12425Y,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12425Y,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13725J,abatacept,Orencia,Powder for I.V. infusion 250 mg,rheumatoid arthritis,Subsequent continuing treatment,14604,True,STREAMLINED,Public,4030,2024,AUGUST
12417M,adalimumab,Amgevita,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
10890E,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10890E,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10890E,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10892G,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12328W,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
12328W,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
12328W,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
12328W,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
12328W,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
12328W,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
12328W,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
12328W,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
12328W,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
12328W,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
12415K,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,11523,True,STREAMLINED,Any,4030,2024,AUGUST
12415K,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,11523,True,STREAMLINED,Any,4030,2024,AUGUST
12415K,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,11523,True,STREAMLINED,Any,4030,2024,AUGUST
12415K,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,11523,True,STREAMLINED,Any,4030,2024,AUGUST
12415K,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,11523,True,STREAMLINED,Any,4030,2024,AUGUST
12576X,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled syringe,rheumatoid arthritis,Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13216N,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,11523,True,STREAMLINED,Any,4030,2024,AUGUST
13216N,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,11523,True,STREAMLINED,Any,4030,2024,AUGUST
11748H,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11748H,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11748H,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11748H,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12102Y,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months) - in a patient of any weight being administered a subcutaneous form of this biological medicine,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13209F,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,11604,True,STREAMLINED,Any,4030,2024,AUGUST
13209F,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,11604,True,STREAMLINED,Any,4030,2024,AUGUST
13770R,tofacitinib,Xeljanz,"Oral solution 1 mg per mL, 240 mL",juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13770R,tofacitinib,Xeljanz,"Oral solution 1 mg per mL, 240 mL",juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13770R,tofacitinib,Xeljanz,"Oral solution 1 mg per mL, 240 mL",juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13770R,tofacitinib,Xeljanz,"Oral solution 1 mg per mL, 240 mL",juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11324B,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11324B,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,psoriatic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13696W,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,Subsequent continuing treatment,14485,True,STREAMLINED,Private,4030,2024,AUGUST
10909E,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10909E,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10909E,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13077G,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled pen,psoriatic arthritis,Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12390D,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12390D,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12390D,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12390D,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12390D,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12390D,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9458T,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9458T,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9458T,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9458T,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12577Y,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled pen,rheumatoid arthritis,Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10900Q,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10900Q,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10900Q,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9104E,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13293P,adalimumab,Humira,Injection 20 mg in 0.2 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
11521J,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,non-radiographic axial spondyloarthritis,Continuing treatment,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11521J,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,non-radiographic axial spondyloarthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
1423X,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
1423X,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
1423X,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
1423X,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
11743C,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,giant cell arteritis,Initial treatment,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12084B,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Continuing treatment in a patient weighing at least 30 kg,14088,True,STREAMLINED,Any,4030,2024,AUGUST
13345J,tofacitinib,Xeljanz,Tablet 5 mg,ankylosing spondylitis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13345J,tofacitinib,Xeljanz,Tablet 5 mg,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13345J,tofacitinib,Xeljanz,Tablet 5 mg,ankylosing spondylitis,Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12795K,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12795K,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13685G,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
13763J,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13763J,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13763J,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13763J,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13763J,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13763J,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12364R,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12364R,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12364R,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12364R,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12364R,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12364R,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12364R,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12364R,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12364R,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12364R,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12364R,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12364R,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13332Q,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Continuing treatment,14155,True,STREAMLINED,Private,4030,2024,AUGUST
12625L,upadacitinib,Rinvoq,Tablet 15 mg,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12625L,upadacitinib,Rinvoq,Tablet 15 mg,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12625L,upadacitinib,Rinvoq,Tablet 15 mg,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12625L,upadacitinib,Rinvoq,Tablet 15 mg,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9659J,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9659J,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9659J,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9659J,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9659J,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9659J,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11481G,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11481G,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11481G,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
1476Q,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
1476Q,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
1476Q,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
1476Q,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10895K,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,psoriatic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10895K,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
6496X,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Remicade,Powder for I.V. infusion 100 mg,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Remicade,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Remicade,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Remicade,Powder for I.V. infusion 100 mg,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Remicade,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Remicade,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
6496X,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
11320T,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11320T,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,ankylosing spondylitis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11721X,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,giant cell arteritis,Continuing treatment,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9615C,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9615C,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9615C,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9615C,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9077R,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9077R,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5284D,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12321L,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,non-radiographic axial spondyloarthritis,Initial treatment - Initial 1 (New patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12321L,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,non-radiographic axial spondyloarthritis,Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12321L,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,non-radiographic axial spondyloarthritis,Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12806B,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9089J,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9089J,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9089J,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9089J,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9089J,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9089J,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9089J,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9089J,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5282B,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11979L,upadacitinib,Rinvoq,Tablet 15 mg,rheumatoid arthritis,First Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11979L,upadacitinib,Rinvoq,Tablet 15 mg,rheumatoid arthritis,First Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9090K,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9090K,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9090K,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9090K,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12810F,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12810F,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12568L,guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled pen,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12568L,guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled pen,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12568L,guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled pen,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12568L,guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled pen,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12568L,guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled pen,psoriatic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12568L,guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled pen,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13706J,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,rheumatoid arthritis,Subsequent continuing treatment,14604,True,STREAMLINED,Any,4030,2024,AUGUST
12761P,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12396K,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12396K,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12396K,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12396K,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12396K,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12396K,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12396K,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12396K,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12396K,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12396K,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12396K,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12396K,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9460X,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9460X,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9460X,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9460X,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
1482B,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
1482B,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
1482B,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
1482B,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10898N,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9658H,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9658H,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9658H,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9658H,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9658H,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9658H,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
1419Q,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
1419Q,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
1419Q,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
1419Q,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
14195D,anifrolumab,Saphnelo,Solution concentrate for I.V. infusion 300 mg in 2 mL,systemic lupus erythematosus,Initial treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
14195D,anifrolumab,Saphnelo,Solution concentrate for I.V. infusion 300 mg in 2 mL,systemic lupus erythematosus,Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
14195D,anifrolumab,Saphnelo,Solution concentrate for I.V. infusion 300 mg in 2 mL,systemic lupus erythematosus,Continuing or recommencement of treatment (within 12 months of a treatment break),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10517M,tofacitinib,Xeljanz,Tablet 5 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10517M,tofacitinib,Xeljanz,Tablet 5 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10517M,tofacitinib,Xeljanz,Tablet 5 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10517M,tofacitinib,Xeljanz,Tablet 5 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13737B,tofacitinib,Xeljanz,Tablet 5 mg,juvenile idiopathic arthritis,Continuing treatment,14697,True,STREAMLINED,Any,4030,2024,AUGUST
13304F,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Continuing treatment,14093,True,STREAMLINED,Public,4030,2024,AUGUST
11323Y,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11323Y,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11323Y,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8779C,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8779C,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5283C,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9101B,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12811G,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12811G,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13054C,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled pen,psoriatic arthritis,Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12429E,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12429E,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12429E,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12429E,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12429E,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12429E,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12429E,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12429E,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12429E,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12429E,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12429E,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12429E,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11376R,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11376R,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,ankylosing spondylitis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12554R,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled pen,rheumatoid arthritis,Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11208X,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11208X,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11208X,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11208X,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12363Q,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12363Q,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12363Q,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12363Q,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12363Q,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12363Q,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12363Q,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12363Q,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12363Q,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13774Y,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13774Y,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13774Y,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9663N,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9663N,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12040Q,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,non-radiographic axial spondyloarthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12040Q,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,non-radiographic axial spondyloarthritis,"Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13323F,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Continuing treatment,14179,True,STREAMLINED,Private,4030,2024,AUGUST
10077J,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10077J,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10077J,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10077J,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11211C,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
11211C,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
12590P,guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled syringe,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12590P,guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12590P,guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled syringe,psoriatic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12590P,guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12590P,guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12590P,guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled syringe,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12099T,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment in a patient weighing at least 30 kg,14088,True,STREAMLINED,Any,4030,2024,AUGUST
11204Q,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12435L,adalimumab,Amgevita,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12435L,adalimumab,Amgevita,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12435L,adalimumab,Amgevita,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12435L,adalimumab,Amgevita,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9455P,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9455P,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9455P,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9455P,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9455P,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9455P,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9455P,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9455P,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12648Q,upadacitinib,Rinvoq,Tablet 15 mg,psoriatic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12648Q,upadacitinib,Rinvoq,Tablet 15 mg,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10238W,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10238W,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,psoriatic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13698Y,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13698Y,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13698Y,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13698Y,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13738C,tofacitinib,Xeljanz,"Oral solution 1 mg per mL, 240 mL",juvenile idiopathic arthritis,Continuing treatment,14697,True,STREAMLINED,Any,4030,2024,AUGUST
13684F,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,Subsequent continuing treatment,14621,True,STREAMLINED,Public,4030,2024,AUGUST
13226D,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
13226D,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
13226D,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
13226D,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
12335F,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12335F,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12335F,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12335F,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12335F,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12335F,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12335F,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12335F,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12335F,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12335F,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12335F,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12335F,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
5733R,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5733R,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5733R,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5733R,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
1481Y,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
1481Y,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
1481Y,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
1481Y,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12624K,upadacitinib,Rinvoq,Tablet 15 mg,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12624K,upadacitinib,Rinvoq,Tablet 15 mg,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12624K,upadacitinib,Rinvoq,Tablet 15 mg,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12624K,upadacitinib,Rinvoq,Tablet 15 mg,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11437Y,baricitinib,Olumiant,Tablet 2 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11437Y,baricitinib,Olumiant,Tablet 2 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11437Y,baricitinib,Olumiant,Tablet 2 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11437Y,baricitinib,Olumiant,Tablet 2 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11565Q,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11565Q,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11565Q,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11565Q,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
4284L,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
4284L,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Continuing treatment,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12105D,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of a new treatment cycle after a break of more than 12 months in a patient weighing less than 30 kg),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12105D,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient weighing less than 30 kg),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12105D,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing less than 30 kg),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12384T,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
12384T,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
12384T,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
12384T,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
12384T,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
3446J,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3446J,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3446J,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3446J,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11744D,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,giant cell arteritis,Initial treatment,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11486M,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Public,4030,2024,AUGUST
11486M,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Public,4030,2024,AUGUST
11486M,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Public,4030,2024,AUGUST
11486M,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Public,4030,2024,AUGUST
11734N,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11734N,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11734N,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11734N,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12297F,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,non-radiographic axial spondyloarthritis,"Initial 1 (New patient), Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12297F,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,non-radiographic axial spondyloarthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
14125K,upadacitinib,Rinvoq,Tablet 15 mg,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
9100Y,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9100Y,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9100Y,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9100Y,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9100Y,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9100Y,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9100Y,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9100Y,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9100Y,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9100Y,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10904X,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10904X,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10904X,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9680L,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9680L,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13716X,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,Subsequent continuing treatment,14485,True,STREAMLINED,Private,4030,2024,AUGUST
12327T,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
12327T,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
12327T,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
12327T,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
12327T,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
12327T,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
12327T,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
12327T,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
12327T,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
12327T,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
11196G,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11196G,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10951J,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10951J,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10951J,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10951J,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9087G,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9087G,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9087G,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9087G,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9087G,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9087G,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9087G,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9087G,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13734W,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment,14638,True,STREAMLINED,Public,4030,2024,AUGUST
13734W,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment,14638,True,STREAMLINED,Public,4030,2024,AUGUST
9088H,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9088H,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9088H,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9088H,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13212J,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
13212J,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
13212J,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
12368Y,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
12368Y,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
12368Y,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
12368Y,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
12368Y,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
13692P,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13692P,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13692P,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13692P,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13692P,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13692P,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13692P,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13692P,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13692P,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13692P,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13692P,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13692P,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13692P,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13692P,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13692P,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11720W,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14150,True,STREAMLINED,Any,4030,2024,AUGUST
13311N,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Continuing treatment,14082,True,STREAMLINED,Private,4030,2024,AUGUST
12401Q,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,11604,True,STREAMLINED,Any,4030,2024,AUGUST
12401Q,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,11604,True,STREAMLINED,Any,4030,2024,AUGUST
12401Q,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,11604,True,STREAMLINED,Any,4030,2024,AUGUST
12401Q,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,11604,True,STREAMLINED,Any,4030,2024,AUGUST
12401Q,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,juvenile idiopathic arthritis,Subsequent continuing treatment,11604,True,STREAMLINED,Any,4030,2024,AUGUST
11361Y,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11361Y,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11361Y,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,ankylosing spondylitis,"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11361Y,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8638P,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8638P,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12442W,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12442W,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12442W,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12442W,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12442W,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12442W,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12442W,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12442W,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12442W,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12442W,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12442W,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12442W,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12767Y,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11216H,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",psoriatic arthritis,Subsequent continuing treatment,9156,True,STREAMLINED,Any,4030,2024,AUGUST
13715W,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,Subsequent continuing treatment,14621,True,STREAMLINED,Public,4030,2024,AUGUST
13066Q,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled syringe,psoriatic arthritis,Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11322X,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11322X,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11322X,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13075E,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled pen,ankylosing spondylitis,Balance of supply (including switching formulation) where the full duration of treatment available under a particular treatment phase was not requested in the preceding prescription,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12326R,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
12326R,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
12326R,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
12326R,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
12326R,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
11750K,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11750K,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Continuing Treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10073E,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Continuing Treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10073E,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10073E,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10073E,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10073E,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10073E,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12428D,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12428D,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12428D,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12428D,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12428D,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12428D,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12428D,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12428D,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12428D,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12428D,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12428D,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12428D,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3434R,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3434R,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3434R,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3434R,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,ankylosing spondylitis,"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11321W,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13324G,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Continuing treatment,14164,True,STREAMLINED,Public,4030,2024,AUGUST
5605B,abatacept,Orencia,Powder for I.V. infusion 250 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5605B,abatacept,Orencia,Powder for I.V. infusion 250 mg,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5605B,abatacept,Orencia,Powder for I.V. infusion 250 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5605B,abatacept,Orencia,Powder for I.V. infusion 250 mg,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5605B,abatacept,Orencia,Powder for I.V. infusion 250 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5605B,abatacept,Orencia,Powder for I.V. infusion 250 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11514B,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,Subsequent continuing treatment,9188,True,STREAMLINED,Public,4030,2024,AUGUST
11514B,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,Subsequent continuing treatment,9188,True,STREAMLINED,Public,4030,2024,AUGUST
13350P,upadacitinib,Rinvoq,Tablet 15 mg,non-radiographic axial spondyloarthritis,Initial treatment - Initial 1 (New patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13350P,upadacitinib,Rinvoq,Tablet 15 mg,non-radiographic axial spondyloarthritis,Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13350P,upadacitinib,Rinvoq,Tablet 15 mg,non-radiographic axial spondyloarthritis,Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13350P,upadacitinib,Rinvoq,Tablet 15 mg,non-radiographic axial spondyloarthritis,"Initial 1 (New patient), Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13343G,upadacitinib,Rinvoq,Tablet 15 mg,non-radiographic axial spondyloarthritis,Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13343G,upadacitinib,Rinvoq,Tablet 15 mg,non-radiographic axial spondyloarthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13343G,upadacitinib,Rinvoq,Tablet 15 mg,non-radiographic axial spondyloarthritis,Continuing treatment,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11447L,baricitinib,Olumiant,Tablet 4 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11447L,baricitinib,Olumiant,Tablet 4 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11447L,baricitinib,Olumiant,Tablet 4 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11447L,baricitinib,Olumiant,Tablet 4 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9641K,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9641K,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9641K,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9641K,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13776C,tofacitinib,Xeljanz,"Oral solution 1 mg per mL, 240 mL",juvenile idiopathic arthritis,Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13778E,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13778E,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13778E,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13778E,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13778E,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13778E,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13726K,abatacept,Orencia,Injection 125 mg in 1 mL single dose pre-filled syringe,rheumatoid arthritis,Subsequent continuing treatment,14604,True,STREAMLINED,Any,4030,2024,AUGUST
11201M,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11201M,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
1220F,abatacept,Orencia,Injection 125 mg in 1 mL single dose pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
1220F,abatacept,Orencia,Injection 125 mg in 1 mL single dose pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
1220F,abatacept,Orencia,Injection 125 mg in 1 mL single dose pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
1220F,abatacept,Orencia,Injection 125 mg in 1 mL single dose pre-filled syringe,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13732R,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,14567,True,STREAMLINED,Any,4030,2024,AUGUST
13732R,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,14567,True,STREAMLINED,Any,4030,2024,AUGUST
13222X,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
13222X,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
13222X,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
13751R,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13751R,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13751R,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12762Q,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11538G,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,non-radiographic axial spondyloarthritis,"Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11538G,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,non-radiographic axial spondyloarthritis,Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11538G,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,non-radiographic axial spondyloarthritis,Initial treatment - Initial 1 (New patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11538G,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,non-radiographic axial spondyloarthritis,Initial treatment - Initial 2 (Change or re-commencement of treatment after a break of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11490R,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Subsequent continuing treatment,14504,True,STREAMLINED,Public,4030,2024,AUGUST
11490R,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Subsequent continuing treatment,14504,True,STREAMLINED,Public,4030,2024,AUGUST
11490R,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Subsequent continuing treatment,14504,True,STREAMLINED,Public,4030,2024,AUGUST
12791F,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13312P,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Continuing treatment,14082,True,STREAMLINED,Private,4030,2024,AUGUST
3447K,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3447K,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3447K,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3447K,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11684Y,abatacept,Orencia ClickJect,Injection 125 mg in 1 mL single dose autoinjector,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11684Y,abatacept,Orencia ClickJect,Injection 125 mg in 1 mL single dose autoinjector,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12361N,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12361N,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12361N,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12361N,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12361N,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12361N,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12361N,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12361N,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12361N,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11722Y,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,giant cell arteritis,Continuing treatment,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12787B,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9102C,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9102C,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9102C,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9102C,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9102C,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9102C,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9102C,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9102C,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9102C,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9102C,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9102C,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9102C,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9102C,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9102C,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9102C,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13292N,adalimumab,Humira,Injection 20 mg in 0.2 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
13754X,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13754X,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13754X,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13754X,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13754X,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13754X,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13754X,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13754X,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13754X,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13754X,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13754X,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13754X,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13754X,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13754X,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13754X,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9033K,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12406Y,adalimumab,Humira,Injection 20 mg in 0.2 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12406Y,adalimumab,Humira,Injection 20 mg in 0.2 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12406Y,adalimumab,Humira,Injection 20 mg in 0.2 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12406Y,adalimumab,Humira,Injection 20 mg in 0.2 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11220M,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11220M,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11220M,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11220M,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12307R,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,non-radiographic axial spondyloarthritis,Continuing treatment,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13701D,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
11326D,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13056E,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled pen,psoriatic arthritis,Balance of supply (including switching formulation) where the full duration of treatment available under a particular treatment phase was not requested in the preceding prescription,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13703F,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,14567,True,STREAMLINED,Any,4030,2024,AUGUST
13703F,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,14567,True,STREAMLINED,Any,4030,2024,AUGUST
11198J,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11198J,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11198J,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11198J,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11365E,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11365E,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11365E,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11365E,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13227E,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
13227E,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
13227E,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
5281Y,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5281Y,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12027B,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,non-radiographic axial spondyloarthritis,Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12027B,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,non-radiographic axial spondyloarthritis,Initial treatment - Initial 1 (New patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12027B,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,non-radiographic axial spondyloarthritis,Initial treatment - Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
14276J,adalimumab,Abrilada,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
14276J,adalimumab,Abrilada,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
14276J,adalimumab,Abrilada,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
14276J,adalimumab,Abrilada,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10078K,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10078K,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10078K,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10078K,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10078K,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Continuing Treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10078K,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13755Y,tofacitinib,Xeljanz,Tablet 5 mg,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13755Y,tofacitinib,Xeljanz,Tablet 5 mg,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13755Y,tofacitinib,Xeljanz,Tablet 5 mg,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13755Y,tofacitinib,Xeljanz,Tablet 5 mg,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
1221G,abatacept,Orencia,Injection 125 mg in 1 mL single dose pre-filled syringe,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
1221G,abatacept,Orencia,Injection 125 mg in 1 mL single dose pre-filled syringe,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11693K,abatacept,Orencia ClickJect,Injection 125 mg in 1 mL single dose autoinjector,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11693K,abatacept,Orencia ClickJect,Injection 125 mg in 1 mL single dose autoinjector,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11693K,abatacept,Orencia ClickJect,Injection 125 mg in 1 mL single dose autoinjector,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11693K,abatacept,Orencia ClickJect,Injection 125 mg in 1 mL single dose autoinjector,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11567T,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11567T,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13048R,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled pen,ankylosing spondylitis,Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8737W,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3445H,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3445H,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3445H,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3445H,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11623R,ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11623R,ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,psoriatic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11623R,ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11623R,ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11623R,ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11623R,ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11725D,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11725D,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11725D,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11725D,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13724H,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13724H,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13724H,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13724H,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13724H,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13724H,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13724H,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13724H,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12438P,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,11523,True,STREAMLINED,Any,4030,2024,AUGUST
12438P,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,11523,True,STREAMLINED,Any,4030,2024,AUGUST
12438P,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,11523,True,STREAMLINED,Any,4030,2024,AUGUST
12438P,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,11523,True,STREAMLINED,Any,4030,2024,AUGUST
12438P,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,11523,True,STREAMLINED,Any,4030,2024,AUGUST
10060L,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10060L,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10060L,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10060L,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
11741Y,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11741Y,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11741Y,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11741Y,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12362P,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12362P,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12362P,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12362P,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12362P,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12362P,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12362P,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12362P,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12362P,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12362P,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12362P,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12362P,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13708L,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,First continuing treatment,14629,True,STREAMLINED,Any,4030,2024,AUGUST
11318Q,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,ankylosing spondylitis,"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13330N,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Continuing treatment,14093,True,STREAMLINED,Public,4030,2024,AUGUST
12805Y,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13301C,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14104,True,STREAMLINED,Any,4030,2024,AUGUST
9671B,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9671B,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9671B,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9671B,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9671B,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9671B,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
3450N,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Continuing Treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3450N,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11487N,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
11487N,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
11487N,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9456Q,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9456Q,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9456Q,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9456Q,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12398M,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12398M,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12398M,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12398M,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12398M,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12398M,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12398M,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12398M,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12398M,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3425G,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3425G,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9621J,abatacept,Orencia,Powder for I.V. infusion 250 mg,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9621J,abatacept,Orencia,Powder for I.V. infusion 250 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9621J,abatacept,Orencia,Powder for I.V. infusion 250 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9621J,abatacept,Orencia,Powder for I.V. infusion 250 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9621J,abatacept,Orencia,Powder for I.V. infusion 250 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9621J,abatacept,Orencia,Powder for I.V. infusion 250 mg,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13306H,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14104,True,STREAMLINED,Any,4030,2024,AUGUST
12063X,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,non-radiographic axial spondyloarthritis,Initial treatment - Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12063X,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,non-radiographic axial spondyloarthritis,Initial treatment - Initial 1 (New patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12063X,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,non-radiographic axial spondyloarthritis,Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13700C,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment,14585,True,STREAMLINED,Private,4030,2024,AUGUST
13700C,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,First continuing treatment,14585,True,STREAMLINED,Private,4030,2024,AUGUST
9457R,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9457R,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9457R,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9457R,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9457R,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9457R,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9457R,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9457R,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11215G,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
11215G,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
10899P,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,psoriatic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10899P,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
14286X,adalimumab,Abrilada,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
12028C,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,non-radiographic axial spondyloarthritis,Continuing treatment,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11319R,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11319R,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11319R,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12768B,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13329M,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Continuing treatment,14179,True,STREAMLINED,Private,4030,2024,AUGUST
11372M,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11372M,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11372M,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11372M,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12766X,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12083Y,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing at least 30 kg),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12083Y,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient weighing at least 30 kg),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12083Y,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months in a patient weighing at least 30 kg),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13049T,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled pen,ankylosing spondylitis,Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11373N,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,psoriatic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11373N,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13730P,tofacitinib,Xeljanz,Tablet 5 mg,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
3432P,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3432P,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,psoriatic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12431G,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12431G,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12431G,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12431G,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12431G,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12431G,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12431G,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12431G,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12431G,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12431G,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12431G,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12431G,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
3436W,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3436W,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,ankylosing spondylitis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
14189T,anifrolumab,Saphnelo,Solution concentrate for I.V. infusion 300 mg in 2 mL,systemic lupus erythematosus,Continuing or recommencement of treatment (within 12 months of a treatment break),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
14189T,anifrolumab,Saphnelo,Solution concentrate for I.V. infusion 300 mg in 2 mL,systemic lupus erythematosus,Initial treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
14189T,anifrolumab,Saphnelo,Solution concentrate for I.V. infusion 300 mg in 2 mL,systemic lupus erythematosus,Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13764K,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13764K,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13764K,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13764K,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13764K,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13764K,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10905Y,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10905Y,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10905Y,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13319B,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Continuing treatment,14154,True,STREAMLINED,Public,4030,2024,AUGUST
10954M,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10954M,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13078H,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled syringe,psoriatic arthritis,Balance of supply (including switching formulation) where the full duration of treatment available under a particular treatment phase was not requested in the preceding prescription,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13690M,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,Subsequent continuing treatment,14621,True,STREAMLINED,Public,4030,2024,AUGUST
13721E,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,14567,True,STREAMLINED,Any,4030,2024,AUGUST
13721E,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,14567,True,STREAMLINED,Any,4030,2024,AUGUST
13721E,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,14567,True,STREAMLINED,Any,4030,2024,AUGUST
13721E,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,14567,True,STREAMLINED,Any,4030,2024,AUGUST
13721E,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,14567,True,STREAMLINED,Any,4030,2024,AUGUST
12555T,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled syringe,rheumatoid arthritis,"Balance of supply for Initial treatment, Continuing treatment - subcutaneous form",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12439Q,adalimumab,Amgevita,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12439Q,adalimumab,Amgevita,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12439Q,adalimumab,Amgevita,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12439Q,adalimumab,Amgevita,Injection 20 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10071C,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Continuing Treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10071C,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10071C,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10071C,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10071C,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10071C,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13326J,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Continuing treatment,14155,True,STREAMLINED,Private,4030,2024,AUGUST
12095N,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient weighing at least 30 kg),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12095N,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months in a patient weighing at least 30 kg),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12095N,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing at least 30 kg),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13229G,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
13229G,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
13229G,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
10081N,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Continuing Treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10081N,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10081N,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10081N,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10081N,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10081N,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12005W,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,non-radiographic axial spondyloarthritis,Continuing treatment,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10906B,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10906B,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,ankylosing spondylitis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11219L,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11219L,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11219L,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11219L,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
1464C,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
1464C,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
1464C,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
1464C,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12375H,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12375H,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12375H,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12375H,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12375H,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12375H,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12375H,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12375H,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12375H,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9679K,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9679K,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10056G,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10056G,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10056G,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10056G,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12802T,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12802T,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10894J,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10894J,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10894J,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13069W,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled syringe,ankylosing spondylitis,Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12430F,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12430F,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12430F,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12430F,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12430F,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12430F,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10511F,tofacitinib,Xeljanz,Tablet 5 mg,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10511F,tofacitinib,Xeljanz,Tablet 5 mg,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11482H,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11482H,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11482H,infliximab,Remicade,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
8741C,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8741C,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8741C,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8741C,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8741C,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8741C,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8741C,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8741C,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8741C,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8741C,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9672C,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9672C,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9672C,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9672C,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9672C,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9672C,tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9099X,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9099X,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13727L,abatacept,Orencia ClickJect,Injection 125 mg in 1 mL single dose autoinjector,rheumatoid arthritis,Subsequent continuing treatment,14604,True,STREAMLINED,Any,4030,2024,AUGUST
9459W,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9459W,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9459W,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9459W,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9459W,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9459W,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9459W,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9459W,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10774C,ustekinumab,Stelara,Injection 45 mg in 0.5 mL,psoriatic arthritis,"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10774C,ustekinumab,Stelara,Injection 45 mg in 0.5 mL,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10774C,ustekinumab,Stelara,Injection 45 mg in 0.5 mL,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10774C,ustekinumab,Stelara,Injection 45 mg in 0.5 mL,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12085C,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of a new treatment cycle after a break of more than 12 months in a patient weighing less than 30 kg),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12085C,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient weighing less than 30 kg),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12085C,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing less than 30 kg),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9086F,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9086F,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9086F,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9086F,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8637N,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8637N,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8637N,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
8637N,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11218K,etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
11218K,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
10901R,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13208E,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
13208E,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
13208E,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
13208E,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
13294Q,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Continuing treatment,14154,True,STREAMLINED,Public,4030,2024,AUGUST
10068X,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10068X,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10068X,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10068X,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
11325C,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11325C,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13210G,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
13210G,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
13210G,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14107,True,STREAMLINED,Private,4030,2024,AUGUST
11730J,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11730J,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Continuing Treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9662M,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9662M,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13765L,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13765L,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13765L,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13765L,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13765L,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13765L,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
13702E,baricitinib,Olumiant,Tablet 4 mg,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
10896L,certolizumab pegol,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11488P,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,First continuing treatment,14689,True,STREAMLINED,Private,4030,2024,AUGUST
11488P,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,First continuing treatment,14689,True,STREAMLINED,Private,4030,2024,AUGUST
11488P,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Subsequent continuing treatment,14723,True,STREAMLINED,Private,4030,2024,AUGUST
11488P,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Subsequent continuing treatment,14723,True,STREAMLINED,Private,4030,2024,AUGUST
5734T,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5734T,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5734T,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5734T,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11442F,baricitinib,Olumiant,Tablet 2 mg,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11442F,baricitinib,Olumiant,Tablet 2 mg,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5756Y,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Remicade,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Remicade,Powder for I.V. infusion 100 mg,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Remicade,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Remicade,Powder for I.V. infusion 100 mg,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Remicade,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Remicade,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5756Y,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11515C,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,Subsequent continuing treatment,9472,True,STREAMLINED,Private,4030,2024,AUGUST
11515C,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,Subsequent continuing treatment,9472,True,STREAMLINED,Private,4030,2024,AUGUST
11217J,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Subsequent continuing treatment,14701,True,STREAMLINED,Any,4030,2024,AUGUST
11217J,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,First continuing treatment,14683,True,STREAMLINED,Any,4030,2024,AUGUST
10072D,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10072D,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10072D,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10072D,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10072D,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10072D,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Continuing Treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9657G,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9657G,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9657G,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9657G,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9657G,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9657G,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12794J,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12794J,tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,juvenile idiopathic arthritis,Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11207W,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11207W,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3426H,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3426H,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3426H,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
3426H,golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12376J,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12376J,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12376J,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12376J,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12376J,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12376J,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12376J,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12376J,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12376J,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12376J,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12376J,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12376J,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13691N,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13691N,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13691N,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13691N,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13691N,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13691N,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled pen,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12086D,tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment in a patient weighing less than 30 kg,14084,True,STREAMLINED,Any,4030,2024,AUGUST
12348X,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
12348X,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
12348X,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
12348X,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
12348X,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment,14136,True,STREAMLINED,Public,4030,2024,AUGUST
13689L,baricitinib,Olumiant,Tablet 2 mg,rheumatoid arthritis,Subsequent continuing treatment,14499,True,STREAMLINED,Any,4030,2024,AUGUST
13731Q,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,Subsequent continuing treatment,14485,True,STREAMLINED,Private,4030,2024,AUGUST
11742B,tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,juvenile idiopathic arthritis,Continuing treatment,14150,True,STREAMLINED,Any,4030,2024,AUGUST
12621G,upadacitinib,Rinvoq,Tablet 15 mg,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12621G,upadacitinib,Rinvoq,Tablet 15 mg,ankylosing spondylitis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12400P,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12400P,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12400P,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12400P,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12400P,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12400P,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12400P,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12400P,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12400P,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12400P,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12400P,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12400P,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12209N,ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,ankylosing spondylitis,Continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12209N,ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12365T,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,11604,True,STREAMLINED,Any,4030,2024,AUGUST
12365T,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,11604,True,STREAMLINED,Any,4030,2024,AUGUST
12365T,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,11604,True,STREAMLINED,Any,4030,2024,AUGUST
12365T,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,11604,True,STREAMLINED,Any,4030,2024,AUGUST
12365T,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,11604,True,STREAMLINED,Any,4030,2024,AUGUST
13057F,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled syringe,ankylosing spondylitis,Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12399N,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12399N,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12399N,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12399N,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12399N,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12399N,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12399N,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12399N,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12399N,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,juvenile idiopathic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12378L,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12378L,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12378L,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12378L,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12378L,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12378L,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12378L,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12378L,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12378L,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12378L,adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12378L,adalimumab,Yuflyma,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12378L,adalimumab,Adalicip,Injection 40 mg in 0.4 mL pre-filled syringe,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12013G,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,non-radiographic axial spondyloarthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12013G,certolizumab pegol,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,non-radiographic axial spondyloarthritis,"Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
12443X,adalimumab,Humira,Injection 20 mg in 0.2 mL pre-filled syringe,juvenile idiopathic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12443X,adalimumab,Humira,Injection 20 mg in 0.2 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12443X,adalimumab,Humira,Injection 20 mg in 0.2 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
12443X,adalimumab,Humira,Injection 20 mg in 0.2 mL pre-filled syringe,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
13349N,tofacitinib,Xeljanz,Tablet 5 mg,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13349N,tofacitinib,Xeljanz,Tablet 5 mg,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13349N,tofacitinib,Xeljanz,Tablet 5 mg,ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13349N,tofacitinib,Xeljanz,Tablet 5 mg,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9036N,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,psoriatic arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9036N,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,psoriatic arthritis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
10893H,secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,ankylosing spondylitis,"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13707K,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",rheumatoid arthritis,First continuing treatment,14629,True,STREAMLINED,Any,4030,2024,AUGUST
9035M,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,psoriatic arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9035M,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,psoriatic arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9035M,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,psoriatic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9035M,etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,psoriatic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13705H,abatacept,Orencia,Powder for I.V. infusion 250 mg,rheumatoid arthritis,Subsequent continuing treatment,14555,True,STREAMLINED,Private,4030,2024,AUGUST
13744J,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13744J,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13744J,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13744J,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13744J,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13744J,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13744J,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13744J,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13744J,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13744J,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13744J,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13744J,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13744J,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13744J,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
13744J,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9078T,adalimumab,Abrilada,Injection 40 mg in 0.8 mL pre-filled syringe,ankylosing spondylitis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11989B,upadacitinib,Rinvoq,Tablet 15 mg,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11989B,upadacitinib,Rinvoq,Tablet 15 mg,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11989B,upadacitinib,Rinvoq,Tablet 15 mg,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11989B,upadacitinib,Rinvoq,Tablet 15 mg,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5753T,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Remicade,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Remicade,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Remicade,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Remicade,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,Continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Remicade,Powder for I.V. infusion 100 mg,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,First continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Inflectra,Powder for I.V. infusion 100 mg,ankylosing spondylitis,"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Remicade,Powder for I.V. infusion 100 mg,ankylosing spondylitis,"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5753T,infliximab,Renflexis,Powder for I.V. infusion 100 mg,ankylosing spondylitis,"Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply",,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
9673D,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9673D,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9673D,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9673D,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9673D,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
9673D,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,rheumatoid arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months),,False,AUTHORITY_REQUIRED,Private,4030,2024,AUGUST
10064Q,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10064Q,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10064Q,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
10064Q,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
12553Q,infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled syringe,rheumatoid arthritis,Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11443G,baricitinib,Olumiant,Tablet 4 mg,rheumatoid arthritis,First continuing treatment,,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
11443G,baricitinib,Olumiant,Tablet 4 mg,rheumatoid arthritis,First continuing treatment - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9085E,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9085E,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9085E,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9085E,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9085E,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9085E,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Initial treatment - Initial 1 (new patient),,False,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9085E,etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
9085E,etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",ankylosing spondylitis,Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply,,True,AUTHORITY_REQUIRED,Any,4030,2024,AUGUST
5735W,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply,,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5735W,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5735W,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
5735W,etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",juvenile idiopathic arthritis,Initial treatment - Initial 1 (new patient),,True,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11497D,infliximab,Inflectra,Powder for I.V. infusion 100 mg,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11497D,infliximab,Renflexis,Powder for I.V. infusion 100 mg,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11497D,infliximab,Remicade,Powder for I.V. infusion 100 mg,psoriatic arthritis,Subsequent continuing treatment,,False,AUTHORITY_REQUIRED,Public,4030,2024,AUGUST
11483J,infliximab,Inflectra,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Subsequent continuing treatment,14505,True,STREAMLINED,Private,4030,2024,AUGUST
11483J,infliximab,Remicade,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Subsequent continuing treatment,14505,True,STREAMLINED,Private,4030,2024,AUGUST
11483J,infliximab,Renflexis,Powder for I.V. infusion 100 mg,rheumatoid arthritis,Subsequent continuing treatment,14505,True,STREAMLINED,Private,4030,2024,AUGUST
13338B,tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,juvenile idiopathic arthritis,Continuing treatment,14082,True,STREAMLINED,Private,4030,2024,AUGUST